• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel

    Jocelyn Aspa
    Jul. 24, 2018 08:49AM PST
    Pharmaceutical Investing

    EyeGate Pharmaceuticals (NASDAQ:EYEG) has announced that the US Food and Drug Administration (FDA) has approved two of the company’s Investigational Device Exemption (IDE) applications for pilot studies of the company’s Ocular Bandage Gel (OBG) product for acceleration of re-epithelialization of large corneal epithelial defects in patients who underwent photorefractive keratectomy (PRK). As quoted in the …

    EyeGate Pharmaceuticals (NASDAQ:EYEG) has announced that the US Food and Drug Administration (FDA) has approved two of the company’s Investigational Device Exemption (IDE) applications for pilot studies of the company’s Ocular Bandage Gel (OBG) product for acceleration of re-epithelialization of large corneal epithelial defects in patients who underwent photorefractive keratectomy (PRK).

    As quoted in the press release:

    EyeGate anticipates entering the clinic for both indications in the third quarter of 2018.

    Stephen From, EyeGate’s Chief Executive Officer, said, “Receiving FDA approval for both pilot studies is a significant milestone in the development of our EyeGate OBG platform.” Mr. From continued, “EyeGate is very pleased to have received these approvals and we look forward to getting these studies underway, as we expect to initiate the clinical trials in the third quarter.”

    The PRK pilot study will enroll up to 45 subjects undergoing a bilateral procedure in a reading center masked trial. The trial intends to compare EyeGate OBG to the current standard of care, bandage contact lens (BCL) plus artificial tears. The primary endpoint will be the percentage of subjects achieving complete wound healing (based on staining) on day 3.

    The PE study will enroll 30 patients in a two arm, 6-week trial with 15 patients per arm. PE is being defined in this trial by fluorescein staining of the cornea using the NEI scale. The primary performance outcome will be the change in NEI corneal staining score from day 0 to day 28 between the OBG arm and the comparator arm.

    Click here to read the full press release.

     

    pharmaceutical investingfda approval
    The Conversation (0)

    Go Deeper

    AI Powered
    Life Science Outlook: World Edition

    Life Science Outlook: World Edition

    Ocumteics Technology President and CEO Dean Burns

    Ocumetics Eyes First In-human Trials of Accommodating Lens Technology in Early 2024

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Invion Limited

    IVX:AU

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES